(HealthDay News) — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those ...
Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback